- What other names is Apricot Kernel known by?
- What is Apricot Kernel?
- How does Apricot Kernel work?
- Are there safety concerns?
- Dosing considerations for Apricot Kernel.
Amandes d'Abricot, Amygdalin, Amygdaline, Amygdaloside, Amygdalus armeniaca, Apricot Almonds, Apricot Kernel Oil, Apricot Seed, Armeniaca vulgaris, Bitter Almonds, Bitter Apricot Kernel, Chinese Almond, Graine d'Abricot, Hueso de Albaricoque, Hueso de Albaricoque de Damasco, Huile de Noyau d'Abricot, Laetrile, Laétrile, Madelonitrile, Noyau d'Abricot, Prunus armeniaca, Prunus Kernel, Vitamin B17, Vitamine B17, Xing Ren.
Apricot kernel is the inner part of the seed of the apricot fruit. The kernel is used to produce oil and other chemicals used for medicinal purposes.
Despite serious safety concerns, apricot kernel is used for treating cancer. It is taken by mouth or given as an injection.
Possibly Ineffective for...
- Cancer. Taking apricot kernel or amygdaline (Laetrile), the active chemical in apricot kernel, by mouth does not seem to be effective for treating cancer.
Insufficient Evidence to Rate Effectiveness for...
Apricot kernel contains a toxic chemical known as amygdalin. In the body this chemical is converted to cyanide, which is poisonous. There was interest in using apricot kernel to fight cancer because it was thought that amygdalin was taken up first by cancer cells and converted to cyanide. It was hoped that the cyanide would harm only the tumor. But research has shown that this is not true. The amygdalin is actually converted to cyanide in the stomach. The cyanide then goes throughout the body, where it can cause serious harm, including death.
Apricot kernel is LIKELY UNSAFE to take by mouth or to use intravenously (by IV). It contains a toxic chemical known as amygdalin. In the body this chemical is converted to cyanide which can cause serious side effects, including death.
Special Precautions & Warnings:Pregnancy and breast-feeding: Apricot kernel is LIKELY UNSAFE for pregnant and breast-feeding women when taken by mouth.
The appropriate dose of apricot kernel depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for apricot kernel. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.
Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).
Health Solutions From Our Sponsors
Ames, M. M., Moyer, T. P., Kovach, J. S., Moertel, C. G., and Rubin, J. Pharmacology of amygdalin (laetrile) in cancer patients. Cancer Chemother.Pharmacol 1981;6(1):51-57. View abstract.
Chandeler, R. F. et al. Laetrile in Perspective. Can Pharm J 1984;117:517.
Cho, A. Y., Yi, K. S., Rhim, J. H., Kim, K. I., Park, J. Y., Keum, E. H., Chung, J., and Oh, S. Detection of abnormally high amygdalin content in food by an enzyme immunoassay. Mol.Cells 4-30-2006;21(2):308-313. View abstract.
Davignon, J. P., Trissel, L. A., and Kleinman, L. M. Pharmaceutical assessment of amygdalin (Laetrile) products. Cancer Treat.Rep. 1978;62(1):99-104. View abstract.
Greenberg, D. M. The case against laetrile: the fraudulent cancer remedy. Cancer 2-15-1980;45(4):799-807. View abstract.
Milazzo, S., Ernst, E., Lejeune, S., and Schmidt, K. Laetrile treatment for cancer. Cochrane.Database.Syst.Rev 2006;(2):CD005476. View abstract.
Milazzo, S., Lejeune, S., and Ernst, E. Laetrile for cancer: a systematic review of the clinical evidence. Support.Care Cancer 2007;15(6):583-595. View abstract.
Moertel, C. G., Ames, M. M., Kovach, J. S., Moyer, T. P., Rubin, J. R., and Tinker, J. H. A pharmacologic and toxicological study of amygdalin. JAMA 2-13-1981;245(6):591-594. View abstract.
Moertel, C. G., Fleming, T. R., Rubin, J., Kvols, L. K., Sarna, G., Koch, R., Currie, V. E., Young, C. W., Jones, S. E., and Davignon, J. P. A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N.Engl.J.Med. 1-28-1982;306(4):201-206. View abstract.
Newton, G. W., Schmidt, E. S., Lewis, J. P., Conn, E., and Lawrence, R. Amygdalin toxicity studies in rats predict chronic cyanide poisoning in humans. West J Med 1981;134(2):97-103. View abstract.
Osterberg, S. [Dangerous to eat: apricot seed preparation]. Lakartidningen 9-27-1978;75(39):3438. View abstract.
Rauws, A. G., Olling, M., and Timmerman, A. The pharmacokinetics of amygdalin. Arch Toxicol. 1982;49(3-4):311-319. View abstract.
Rauws, A. G., Olling, M., and Timmerman, A. The pharmacokinetics of prunasin, a metabolite of amygdalin. J Toxicol.Clin Toxicol. 1982;19(8):851-856. View abstract.
Rubino, M. J. and Davidoff, F. Cyanide poisoning from apricot seeds. JAMA 1-26-1979;241(4):359. View abstract.
Sadoff, L., Fuchs, K., and Hollander, J. Rapid death associated with laetrile ingestion. JAMA 4-14-1978;239(15):1532. View abstract.
Suchard, J. R., Wallace, K. L., and Gerkin, R. D. Acute cyanide toxicity caused by apricot kernel ingestion. Ann.Emerg.Med. 1998;32(6):742-744. View abstract.
Tlirnoveanu, C., Popescu, E., Negulescu, I., Georgescu, M. I., Cighir, R., Calarasu, M., and Azzola, M. [Study of acute poisonings with cyanogenetic substances (apricot seed kernels)]. Rev.Pediatr.Obstet.Ginecol.Pediatr. 1982;31(3):249-252. View abstract.
Unproven methods of cancer management. Laetrile. CA Cancer J Clin 1991;41(3):187-192. View abstract.
Anon. FDA takes action against firms marketing unapproved drugs. FDA. 2000. http://web.archive.org/web/20001017134529/http://www.fda.gov/bbs/topics/ANSWERS/ANS01032.html
Anon. Laetrile (Amygdalin, other Names). FDA. 1987. Available at: www.accessdata.fda.gov/cms_ia/importalert_167.html.
Anon. Postscript on laetrile. FDA. 1987. Available at: http://web.archive.org/web/19970506021729/http://www.fda.gov/bbs/topics/ANSWERS/ANS00309.html